Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12)

CD40‐CD40 ligand interactions are crucial to cognate interactions between T cells, B cells and antigen‐presenting cells (APC), and contribute to non‐antigen‐specific effector functions of APC in inflammatory disorders. Here we demonstrate that functional blockade of CD40 with an antagonist mouse anti‐human CD40 monoclonal antibody (mAb mu5D12) effectively prevents clinical expression of chronic demyelinating experimental autoimmune encephalomyelitis (EAE) in outbred marmoset monkeys, a preclinical model of multiple sclerosis. Anti‐CD40 mAb interfered with development of clinical symptoms of marmoset EAE during the treatment period, even when treatment was started several weeks after T cell priming. Magnetic resonance imaging demonstrated inflammatory activity in the brain at initiation of antibody treatment, confirming that treatment interfered with the disease process. Access of therapeutic anti‐CD40 to potential sites of action, the secondary lymphoid organs and the brain white matter lesions, was visualized in situ. The present data are the first to demonstrate the clinical potential of blocking APC and effector cell functions using murine antagonist anti‐CD40 mAb in the treatment of chronic inflammatory diseases.

[1]  L. Boon,et al.  Prevention of Experimental Autoimmune Encephalomyelitis in the Common Marmoset (Callithrix jacchus) Using a Chimeric Antagonist Monoclonal Antibody Against Human CD40 Is Associated with Altered B Cell Responses1 , 2001, The Journal of Immunology.

[2]  B. Becher,et al.  The Clinical Course of Experimental Autoimmune Encephalomyelitis and Inflammation Is Controlled by the Expression of Cd40 within the Central Nervous System , 2001, The Journal of experimental medicine.

[3]  K. Nicolay,et al.  Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24–36 Is Presented by a Monomorphic MHC Class II Molecule1 , 2000, The Journal of Immunology.

[4]  L. Boon,et al.  A new primate model for multiple sclerosis in the common marmoset. , 2000, Immunology today.

[5]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[6]  S. Miller,et al.  Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. , 1999, The Journal of clinical investigation.

[7]  H. Lassmann,et al.  Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). , 1998, The American journal of pathology.

[8]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[9]  M. Kap,et al.  Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide , 1998, Multiple sclerosis.

[10]  S. Kaveri,et al.  Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein , 1998, European journal of immunology.

[11]  H. Lassmann,et al.  Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus) , 1998, Journal of Neuroimmunology.

[12]  J. Laman,et al.  CD40-CD40L interactions in atherosclerosis. , 1997, Immunology today.

[13]  R. Bontrop,et al.  The common marmoset: A new world primate species with limited Mhc class II variability , 1997 .

[14]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis , 1997, The Lancet.

[15]  S. Hauser,et al.  Creation of a model for multiple sclerosis in Callithrix jacchus marmosets , 1997, Journal of Molecular Medicine.

[16]  H. Weiner,et al.  Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[18]  C. Janeway,et al.  Requirement for CD40 Ligand in Costimulation Induction, T Cell Activation, and Experimental Allergic Encephalomyelitis , 1996, Science.

[19]  J. Ceuppens,et al.  Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin‐12 for interferon‐γ production , 1996, European journal of immunology.

[20]  A. Aruffo,et al.  CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Letvin,et al.  Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. , 1995, The Journal of clinical investigation.

[22]  N. Letvin,et al.  Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis , 1995, Annals of neurology.

[23]  G. Kingsley,et al.  Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis , 1994, European journal of immunology.

[24]  J. V. van Noort,et al.  Fractionation of central nervous system myelin proteins by reversed-phase high-performance liquid chromatography. , 1994, Journal of chromatography. B, Biomedical applications.

[25]  J. Kwekkeboom,et al.  Helper effector function of human T cells stimulated by anti‐CD3 mAb can be enhanced by co‐stimulatory signals and is partially dependent on CD40‐CD40 ligand interaction , 1994, European journal of immunology.

[26]  J. Ceuppens,et al.  Ligation of B7 with CD28/CTLA‐4 on T cells results in CD40 ligand expression, interleukin‐4 secretion and efficient help for antibody production by B cells , 1993, European journal of immunology.

[27]  J. Laman,et al.  New immunoenzyme-cytochemical stainings for the in situ detection of epitope specificity and isotype of antibody forming B cells in experimental and natural (auto) immune responses in animals and man. , 1992, Journal of immunological methods.

[28]  N. Van Rooijen,et al.  Double immunocytochemical staining for in vivo detection of epitope specificity and isotype of antibody-forming cells against synthetic peptides homologous to human immunodeficiency virus-1. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  H. Powell,et al.  Pathology of multiple sclerosis. , 1983, Neurologic clinics.

[30]  M. Daemen,et al.  CD40-CD40L interactions in atherosclerosis. , 2002, Trends in cardiovascular medicine.

[31]  A. Heath,et al.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies , 1998, Nature Medicine.

[32]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. , 1997, Lancet.

[33]  P. Knopf,et al.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. , 1992, Immunology today.